News

Demand for the healthcare leader's weight-loss drugs continues to rise.

(Bloomberg) -- Stocks in Asia were poised to ease Thursday as investors digested gains in technology shares while watching for fresh signs of progress toward a deal to reopen the Strait of Hormuz.Most Read from BloombergIran Says Agreement on Hormuz Shipping Reached With OmanSpaceX’s AI Splurge Puts a Damper on First Earnings After IPOTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasit

Moby summary of Charles River Laboratories International, Inc.'s Q2 2026 earnings call

The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.

Eli Lilly and Co (LLY) raises full-year 2026 guidance after Q2 revenue jumps 48%, driven by blockbuster incretin sales and strong international expansion.

Eli Lilly raised its revenue outlook after Mounjaro and Zepbound generated nearly two-thirds of quarterly sales.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

Key takeawaysEli Lilly’s second-quarter revenue surged 48 per cent to US$22. 97 billion, beating Wall Street expectations by more than US$2 billion.

A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain.

Eli Lilly just posted numbers that stunned Wall Street, but the company's own executives admit a single bottleneck could cap how far the GLP-1 juggernaut actually runs, and the next move to break through it is already in motion.

Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.

CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-cons

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and th

Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.

On Aug. 5, 2026, new highs across major indexes reflect renewed confidence in global trade as investor confidence starts to return.

BUSINESS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0429 ET – Novo Nordisk’s second-quarter earnings beat and guidance raise imply minimal changes to the midpoint of consensus estimates, Bernstein analysts write.

Set against the backdrop of a mixed Q2, Novo is eyeing bolt-ons in favour of transformative acquisitions.

US equities were mixed and crude oil eased in late-morning trading Wednesday as investors remained h

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

The Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline stumble.

July Private Payrolls Well Below Expectations .

Today's ADP private-sector payrolls came in below the +75K forecast and less than half the downwardly revised +95K from June.

Investors have plenty of reasons to be uncertain right now. But that has not wholly shaken companies' faith in their ability to deliver strong earnings growth this year.

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Eli Lilly (NYSE:LLY) rose more than 5% in pre-market trading on Wednesday after the pharmaceutical company increased its full-year revenue guidance, supported by continued strong demand for its blockbuster diabetes and weight-loss treatments. The revised outlook outweighed an earnings-per-share miss for the second quarter, as investors focused on accelerating sales growth and improved profitability expectations.

Eli Lilly raised its 2026 sales forecast as its GLP-1 drugs outperformed expectations in Q2.

The S&P 500 climbed 0.6% on Wednesday, while SpaceX stock slumped more than 10% on its first quarterly report since going public

Outside the U.S., volume climbed 113% against a 36% drop in realized prices

Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may not be what defines the company a decade from now. A billion-dollar bet on artificial intelligence could change everything.

Zepbound and Mounjaro helped drive a major earnings beat and a higher sales outlook.